The Clinical Trials Support Resource (CTSR) supports clinical trials through administrative support, information technology, and regulatory affairs. The CTSR complements the Protocol Review and Monitoring System (PRMS) and encourages the advancement of cancer research. CTSR is supported by 49 staff members under the direction of Dr. Maurie Markman, Vice President for Clinical Research. Administrative Support within the CTSR supplies infrastructure for the day-to-day operational management of the clinical research program. This includes central management and oversight functions for coordinating and reporting on clinical research protocols. Regulatory Affairs Support from the CTSR is dedicated to servicing the needs of the clinical investigators and adhering to the highest standards of clinical research compliance with local, state and federal regulations. CTSR provides centralized support for the submission, review, approval, activation, modification, continuing review and termination of protocols involving human subjects research. This includes the staffing of the Institutional Review Board (IRB) and the Data Monitoring Committee (DMC). The staff coordinates and maintains regulatory data for tracking the life cycle of the research protocols. These regulatory documents are part of the master protocol file in CTSR and are in both electronic and paper media. Information Technology Support within the CTSR comes from the Research Applications Information System (RAIS) staff who support the development and maintenance of centralized databases for research-related regulatory and clinical data. The Protocol Data Management System (PDMS) and the Clinical Oncology Research system (CORe), provide structure and tools to manage and share clinical research data. The Protocol Document On-Line (POOL) database supports and facilitates the complete life cycle of the protocol document, including the submission, review and approval processes performed by the Clinical Research Committee and Institutional Review Board (IRB) meetings. During the last fiscal year, the funds used to support the CTSR salaries were $475,485 (25%) from the Cancer Center Support Grant (CCSG), $172,163 (9%) from user fees and $1,295,771 (66%) from the Institution. In the next award cycle, the level of support from the CCSG, the user fees and the institution is projected to be closer to 22% and 12% and 66%, respectively. The CTSR supported 2739 protocols from 599 cancer center members, of whom 81% hold peer-reviewed funding. During the last several years, the number of new protocols managed by CTSR has remained constant. Protocols that do not meet the UTMDACC scientific standards are typically withdrawn from submission and review. While the volume of protocols has not increased, the oversight of clinical research has become increasingly complex and time-consuming due to evolving regulatory requirements and the current research climate.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :
Cassani, Lisa S; Raju, Gottumukkala S (2016) Techniques for management of bleeding associated with colonic endoscopic mucosal resection. Gastrointest Endosc 83:469-70
Zargar, Homayoun; Atwell, Thomas D; Cadeddu, Jeffrey A et al. (2016) Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. Eur Urol 69:116-28
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2016) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res :
Jinesh, Goodwin G; Kamat, Ashish M (2016) Endocytosis and serpentine filopodia drive blebbishield-mediated resurrection of apoptotic cancer stem cells. Cell Death Discov 2:
Maiti, Abhishek; Cortes, Jorge E; Brown, Yolanda D et al. (2016) Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leuk Lymphoma :1-4
Visone, R; Pallante, P; Vecchione, A et al. (2016) Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 35:5214
Zhou, Fuling; Li, Ming; Wei, Yongchang et al. (2016) Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells. Oncotarget :
Gamaletsou, Maria N; Rammaert, Blandine; Bueno, Marimelle A et al. (2016) Candida Arthritis: Analysis of 112 Pediatric and Adult Cases. Open Forum Infect Dis 3:ofv207
Parra, Edwin R; Behrens, Carmen; Rodriguez-Canales, Jaime et al. (2016) Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res :

Showing the most recent 10 out of 9121 publications